We discover new drug candidates with proven safety and efficacy, target diseases with unmet medical needs such as rare and incurable diseases, and cancer, and invest heavily in licensing and research and development to achieve the final product. We aim to commercialize and improve the quality of human life. To this end, we pursue rare disease indications and utilize rapid and advantageous development paths, and strengthen our pipeline for various disease groups through a global partnership research and development (R&D) network to continue strategic research and development for new drug development and strengthen our capabilities.
Safety and Efficacy verification
We focus on new drug candidates whose safety and efficacy have already been proven to shorten the development period and increase the likelihood of success.
Selection and focus
We focus on rare and incurable diseases and cancers with unmet medical needs, increasing the success rate of development and quickly providing treatments to patients.
Pursuing rare disease indications
Through rare disease indications, we maximize the efficiency of new drug development by utilizing a rapid and advantageous development path.
potential Innovative
new drug candidate
Expand new drug development opportunities by strengthening pipelines for various disease groups.
Continued strategic
research and development
Through global partnerships, we strengthen our research and development capabilities and achieve sustainable growth.
Research & Development
Our Key Asset
Most diseases that require unmet medical needs, such as Osteogenesis Imperfecta and Rett Syndrome, are either in off-label use with low effectiveness and severe side effects, or have no currently approved treatments.
We will continue to strive to resolve unmet medical needs and provide a better life for our patients.
Rare and incurable diseases can be developed quickly with Orphan Drug Designation (ODD), can be licensed as orphan drugs approved through small-scale clinical trials, and have the opportunity to monopolize the market.
Elocalcitol inhibits inflammation and immune responses by blocking the NF-kB signaling pathway.
NF-kB (Nuclear Factor kappa-B) is a transcription factor that plays an important role in various physiological processes, including inflammation, immunity, and cell death. NF-kB is generally present in the cytoplasm, and moves to the nucleus upon specific stimulation to regulate the expression of target genes.
Elocalcitol may be utilized in the treatment of a variety of conditions involving NF-kB activation, including inflammatory diseases, autoimmune diseases, and cancer.
News & Notice
